Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Protein misfolding has been implicated in a large number of diseases termed protein- folding disorders (PFDs), which include Alzheimer's disease, Parkinson's disease, transmissible spongiform encephalopathies, familial amyloid polyneuropathy, Huntington's disease, and type II diabetes. In these diseases, large quantities of incorrectly folded proteins undergo aggregation, destroying brain cells and other tissues. The interplay between ligand binding and hydration is an important component of the formation of misfolded protein species. Hydration drives various biological processes, including protein folding, ligand binding, macromolecular assembly, enzyme kinetics, and signal transduction. The changes in hydration and packing, both when proteins fold correctly or when folding goes wrong, leading to PFDs, are examined through several biochemical, biophysical, and structural approaches. Although in many cases the binding of a ligand such as a nucleic acid helps to prevent misfolding and aggregation, there are several examples in which ligands induce misfolding and assembly into amyloids. This occurs simply because the formation of structured aggregates (such as protofibrillar and fibrillar amyloids) involves decreases in hydration, formation of a hydrogen-bond network in the secondary structure, and burying of nonpolar amino acid residues, processes that also occur in the normal folding landscape. In this Account, we describe the present knowledge of the folding and misfolding of different proteins, with a detailed emphasis on mammalian prion protein (PrP) and tumoral suppressor protein p53; we also explore how ligand binding and hydration together influence the fate of the proteins. Anfinsen's paradigm that the structure of a protein is determined by its amino acid sequence is to some extent contradicted by the observation that there are two isoforms of the prion protein with the same sequence: the cellular and the misfolded isoform. The cellular isoform of PrP has a disordered N-terminal domain and a highly flexible, not-well-packed C-terminal domain, which might account for its significant hydration. When PrP binds to biological molecules, such as glycosaminoglycans and nucleic acids, the disordered segments appear to fold and become less hydrated. Formation of the PrP-nucleic acid complex seems to accelerate the conversion of the cellular form of the protein into the disease-causing isoform. For p53, binding to some ligands, including nucleic acids, would prevent misfolding of the protein. Recently, several groups have begun to analyze the folding-misfolding of the individual domains of p53, but several questions remain unanswered. We discuss the implications of these findings for understanding the productive and incorrect folding pathways of these proteins in normal physiological states and in human disease, such as prion disorders and cancer. These studies are shown to lay the groundwork for the development of new drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
Prions and their partners in crime
Caughey, B., & Baron, G. S. (2006) · Nature · doi:10.1038/nature05294 · Cited by 295
Cited by
Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils
Ano Bom, A. P. D., Rangel, L. P., Costa, D. C. F., de Oliveira, G. A. P., Sanches, D., Braga, C. A., Gava, L. M., Ramos, C. H. I., Cepeda, A. O. T., Stumbo, A. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340638 · Cited by 280
Self-citationPrion-like aggregation of mutant p53 in cancer
Silva, J. L., Gallo, C. V. D. M., Costa, D. C. F., & Rangel, L. P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.001 · Cited by 201
Self-citationMolecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2
Wiech, M., Olszewski, M. B., Tracz-Gaszewska, Z., Wawrzynow, B., Zylicz, M., & Zylicz, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051426 · Cited by 129
Energy Landscape of the Prion Protein Helix 1 Probed by Metadynamics and NMR
Camilloni, C., Schaal, D., Schweimer, K., Schwarzinger, S., & De Simone, A. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2011.12.003 · Cited by 45
Metadata
- Authors
- Silva, J. L., Vieira, T. C. R. G., Gomes, M. P. B., Bom, A. P. A., Lima, L. M. T. R., Freitas, M. S., Ishimaru, D., Cordeiro, Y., & Foguel, D.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-10-09
- Volume
- 43
- Issue
- 2
- Pages
- 271-279
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W1984876762
- Cited by
- 118
- References
- 3
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.